Literature DB >> 21622138

Sanggenon C decreases tumor cell viability associated with proteasome inhibition.

Hongbiao Huang1, Ningning Liu, Kai Zhao, Chenchen Zhu, Xiaoyu Lu, Shujue Li, Wen Lian, Ping Zhou, Xiaoxian Dong, Canguo Zhao, Haiping Guo, Change Zhang, Changshan Yang, Guanmei Wen, Li Lu, Xiaofen Li, Lixia Guan, Chunjiao Liu, Xuejun Wang, Qing Ping Dou, Jinbao Liu.   

Abstract

Several flavonoids have been reported to be proteasome inhibitors, but whether prenylated flavonoids are able to inhibit proteasome function remains unknown. We report for the first time that Sanggenon C, a natural prenylated flavonoid, inhibits tumor cellular proteasomal activity and cell viability. We found that (1) Sanggenon C inhibited tumor cell viability and induced cell cycle arrest at G0/G1 phase; (2) Sanggenon C inhibited the chymotrypsin-like activity of purified human 20S proteasome and 26S proteasome in H22 cell lysate, and Sanggenon C was able to dose-dependently accumulate ubiquitinated proteins and proteasome substrate protein p27; (3) Sanggenon C-induced proteasome inhibition occurred prior to cell death in murine H22 and P388 cell lines; (4) Sanggenon C induced death of human K562 cancer cells and primary cells isolated from leukemic patients. We conclude that Sanggenon C inhibits tumor cell viability via induction of cell cycle arrest and cell death, which is associated with its ability to inhibit the proteasome function and that proteasome inhibition by Sanggenon C at least partially contributes to the observed tumor cell growth-inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622138      PMCID: PMC3303154          DOI: 10.2741/E335

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  29 in total

1.  Inhibitory effect and mechanism of action of sanggenon C on human polymorphonuclear leukocyte adhesion to human synovial cells.

Authors:  Liang-Cheng Li; Fang Shen; Qi Hou; Gui-Fang Cheng
Journal:  Acta Pharmacol Sin       Date:  2002-02       Impact factor: 6.150

2.  A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.

Authors:  Geetha Achanta; Aneta Modzelewska; Li Feng; Saeed R Khan; Peng Huang
Journal:  Mol Pharmacol       Date:  2006-04-24       Impact factor: 4.436

3.  Activation of the cell death program by inhibition of proteasome function.

Authors:  H C Drexler
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

4.  Prenylated flavonoids as tyrosinase inhibitors.

Authors:  Nan Kyoung Lee; Kun Ho Son; Hyeun Wook Chang; Sam Sik Kang; Haeil Park; Moon Young Heo; Hyun Pyo Kim
Journal:  Arch Pharm Res       Date:  2004-11       Impact factor: 4.946

5.  Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.

Authors:  Joseph Pye; Farhad Ardeshirpour; Arlene McCain; Dwight A Bellinger; Elizabeth Merricks; Julian Adams; Peter J Elliott; Christine Pien; Thomas H Fischer; Albert S Baldwin; Timothy C Nichols
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11-07       Impact factor: 4.733

6.  Cytotoxic flavonoids with isoprenoid groups from Morus mongolica.

Authors:  Y Q Shi; T Fukai; H Sakagami; W J Chang; P Q Yang; F P Wang; T Nomura
Journal:  J Nat Prod       Date:  2001-02       Impact factor: 4.050

7.  Protein tyrosine phosphatase 1B inhibitors from Morus root bark.

Authors:  Long Cui; Minkyun Na; Hyuncheol Oh; Eun Young Bae; Dae Gwin Jeong; Seong Eon Ryu; Sohee Kim; Bo Yeon Kim; Won Keun Oh; Jong Seog Ahn
Journal:  Bioorg Med Chem Lett       Date:  2005-12-13       Impact factor: 2.823

8.  Proteasome inhibition induces hepatic stellate cell apoptosis.

Authors:  Akira Anan; Edwina S Baskin-Bey; Steven F Bronk; Nathan W Werneburg; Vijay H Shah; Gregory J Gores
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

9.  A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.

Authors:  Jinbao Liu; Hanqiao Zheng; Mingxin Tang; Youn-Chul Ryu; Xuejun Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-31       Impact factor: 4.733

10.  Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.

Authors:  Huanjie Yang; Ping Zhou; Hongbiao Huang; Di Chen; Ningfang Ma; Qiuzhi Cindy Cui; Shouxing Shen; Weihua Dong; Xiaoyan Zhang; Wen Lian; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

View more
  13 in total

1.  [Sanggenon C induces apoptosis of prostate cancer PC3 cells by activating caspase 3 and caspase 9 pathways].

Authors:  Ping Zhou; Xiao-Xian Dong; Ping Tang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-09-20

2.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

Review 3.  Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds.

Authors:  Ningning Liu; Hongbiao Huang; Q Ping Dou; Jinbao Liu
Journal:  Oncoscience       Date:  2015-05-31

4.  Sanggenon C protects against pressure overload‑induced cardiac hypertrophy via the calcineurin/NFAT2 pathway.

Authors:  Lili Xiao; Yulei Gu; Lu Gao; Jiahong Shangguan; Yang Chen; Yanzhou Zhang; Ling Li
Journal:  Mol Med Rep       Date:  2017-08-18       Impact factor: 2.952

5.  Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids.

Authors:  Katrin Sak; Hele Everaus
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

6.  Sanggenon C induces apoptosis of colon cancer cells via inhibition of NO production, iNOS expression and ROS activation of the mitochondrial pathway.

Authors:  Li-Dong Chen; Zhi-Hui Liu; Lian-Feng Zhang; Jian-Ning Yao; Chun-Feng Wang
Journal:  Oncol Rep       Date:  2017-08-22       Impact factor: 3.906

7.  L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro.

Authors:  Hongbiao Huang; Ningning Liu; Haiping Guo; Siyan Liao; Xiaofen Li; Changshan Yang; Shouting Liu; Wenbin Song; Chunjiao Liu; Lixia Guan; Bing Li; Li Xu; Change Zhang; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

8.  HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.

Authors:  Hongbiao Huang; Ningning Liu; Changshan Yang; Siyan Liao; Haiping Guo; Kai Zhao; Xiaofen Li; Shouting Liu; Lixia Guan; Chunjiao Liu; Li Xu; Change Zhang; Wenbin Song; Bing Li; Ping Tang; Q Ping Dou; Jinbao Liu
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  Therapeutic targeting of cancer cell cycle using proteasome inhibitors.

Authors:  Namrata Rastogi; Durga Prasad Mishra
Journal:  Cell Div       Date:  2012-12-26       Impact factor: 5.130

10.  Sanggenon C protects against cardiomyocyte hypoxia injury by increasing autophagy.

Authors:  Yang Gu; Lu Gao; Yu Chen; Zhuo Xu; Kun Yu; Dongying Zhang; Gang Zhang; Xiwen Zhang
Journal:  Mol Med Rep       Date:  2017-09-27       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.